Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 Study

Background on Capivasertib - now approved for breast cancerПодробнее

Hope S. Rugo on the Approval of the Cooling CapПодробнее

CAPItello-291: capivasertib +fulvestrant for AI-resistant HR+/HER2- advanced breast cancerПодробнее

Results of Capitello291 - CapivasertibПодробнее

Dr. Rugo on Guidelines for the Treatment of Metastatic Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Dr. Hope Rugo | San Antonio Breast Cancer Symposium 2022 | General SessionПодробнее

Dr. Rugo Discusses Guidelines for Metastatic Breast Cancer ManagementПодробнее

Dr. Rugo Discusses the Regulatory Process Behind BiosimilarsПодробнее

Dr. Rugo Discusses the Future of Angiogenesis in Breast CancerПодробнее

Dr. Rugo on SWISH Trial for HR-Positive Breast CancerПодробнее

Dr. Rugo on the Efficacy of Bevacizumab in Breast CancerПодробнее

Breast Cancer | Hope S Rugo, MDПодробнее

Hope Rugo, MD: Advances and Challenges In the Treatment of Metastatic Breast CancerПодробнее

Dr. Rugo on Results of Oral Paclitaxel With Encequidar in Metastatic Breast CancerПодробнее

Dr. Rugo on the Significance of the MONARCH I Trial for Breast CancerПодробнее

Dr. Hope Rugo on Comparative Effectiveness in the NSABP B-38 TrialПодробнее

Dr. Hope Rugo Examines Angiogenesis Inhibition for Advanced Breast CancerПодробнее

Identifying Patients With High-Risk Early Breast Cancer | Insights from Dr Hope RugoПодробнее